Anagenics Limited · ASX:AN1
Anagenics — Medical Therapies — Shareholder Meeting (May 2009)
20 slides from Anagenics's shareholder meeting presentation, May 5, 2009
Slide 1: Medical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1
Slide 2: Agenda
Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for next 18 months 5. Technology information 6. Summary 2
Slide 3: Medical Therapies (ASX:MTY)
Medical Therapies (ASX:MTY) Listed in December 2005 185M shares on issue Midkine specialist and owner of the largest diagnostic and therapeutic patent portfolio around this novel cancer target globally • Developing early cancer diagnostic test • Developing therapeutic antibody portfolio with partner
Slide 4: Recent developments
Recent developments Capital structure and funding •Retired $1.1M convertible debt in February 2009 •Raised $790K for partial debt repayment and working capital in two private placements in February and April 2009 •Retired $1.5M debt in lieu of ordinary shares Product development •Commenced mycoplasm
Slide 5: Recent developments
Recent developments Business development Completed licensing and partnering data packages in the following areas • Therapeutic anti-midkine antibody (Multiple sclerosis and rheumatoid arthritis) • Veterinary cancer diagnostics (Early cancer diagnosis in canines) • Human early cancer diagnostics (Mid
Slide 6: Business strategy – diagnostic portfolio
Business strategy – diagnostic portfolio Commercialise MK cancer diagnostic assets • Complete optimisation of commercial Midkine ELISA • Set up distribution of Midkine ELISA for research • Complete clinical validation of early cancer diagnostic • Complete validation of canine cancer diagnostic test
Slide 7: Business strategy – therapeutic portfolio
Business strategy – therapeutic portfolio Partner or license therapeutic assets • Set up partnership for the humanisation, optimisation and preclinical POC of the anti-midkine antibody assets • License antibody assets for selected indications (RA, MS, restenosis) • Complete validation trials and lic
Slide 8: Key value inflection points
Key value inflection points May 2009 December 2010 Partnership to Antisense and Point of care humanize and siRNA partnership First Ab indication MK assay optimize lead mAb March 2010 license collaboration candidates pre-clinical Nov 2009 Sept 2009 Commence License early License dog Dec 2010 ELISA sa
Slide 9: Midkine, a novel target
Midkine, a novel target Novel target for new therapies and diagnostics against cancer, inflammation and autoimmune diseases Small protein (13kD, 121 AA’s) with two domains Heparin binding growth factor prominent in embryogenesis but largely undetectable in adults Acts by: • reducing apoptosis (cell
Slide 10: Midkine, a novel cancer marker
Midkine, a novel cancer marker Detection of Midkine in serum by using our proprietary Enzyme-linked Immunoassay (ELISA) 10
Slide 11: Midkine levels in cancer patients
Midkine levels in cancer patients Midkine levels were found to be elevated in 87% of cancer patients in 10 different cancers Ikematsu et al., Br. J. Cancer, 2000 11
Slide 12: Midkine in cancer prognosis
Midkine in cancer prognosis Strong correlation of elevated level of blood midkine with poor prognosis of neuroblastoma Ikematsu, et al, British Journal of Cancer 2003 12
Slide 13: Midkine in cancer prognosis
Midkine in cancer prognosis Five year survival curves of 93 patients with oesophageal squamous cell carcinoma show statistically significant survival rate increase amongst patients with 300pg/mlor less Midkine in the blood Hideaki, et al. Cancer Science 2003 13
Slide 14: Midkine antibodies for the treatment of multiple sclerosis
Midkine antibodies for the treatment of multiple sclerosis The role of MK in the development and severity of multiple sclerosis Standard MS animal model (EAE) was used by inducing MS with the administration of MOG35-55 Significant delay of disease onset was observed in mice without the MK gene (MK-/
Slide 15: Antisense Midkine in the treatment of rectal carcinoma
Antisense Midkine in the treatment of rectal carcinoma Anti-midkine antisense reduced growth Anti-midkine antisense dose curve of rectal carcinoma cells against rectal carcinoma in mice Takei, et al. Cancer Research 2001 15
Slide 16: The role of Midkine in rheumatoid arthritis
The role of Midkine in rheumatoid arthritis Midkine levels observed in patients with RA induced in wild type and MK-/- mice rheumatoid arthritis Arthritis Incidence + - WT Mice 6 1 86% MK-/- 1 9 10% MK pump 9 3 75% • 6/7 (86%) WT mice show symptoms using antibody induced arthritis model Increased le
Slide 17: Midkine protein as therapeutic
Midkine protein as therapeutic Midkine therapy following Acute Myocardial Infarction (AMI) Pig model Pig model of AMI - balloon was placed distal to the first diagonal artery for 45 minutes Following ischemia and reperfusion 5 microgram per kilogram MK was injected directly into the Control Midkine
Slide 18: Summary
Summary Advanced diagnostic portfolio with near term revenue potential Veterinary diagnostic and therapeutic portfolio with lower regulatory hurdles and close to revenue Early licensing revenue opportunities for high value therapeutic anti-midkine antibody and anti-midkine oligonucleotide assets Ear
Slide 19: Thank you
Thank you Maria Halasz Chief Executive Officer E: halasz@medicaltherapies.com.au T: +61 2 9299 0311 www.medicaltherapies.com.au 19
Slide 20: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. These statements are not guarantees of Medical Therapies Limited’s future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in the